|
Name |
1,1-Cyclohexanedimethanol
|
Molecular Formula | C8H16O2 | |
IUPAC Name* |
[1-(hydroxymethyl)cyclohexyl]methanol
|
|
SMILES |
C1CCC(CC1)(CO)CO
|
|
InChI |
InChI=1S/C8H16O2/c9-6-8(7-10)4-2-1-3-5-8/h9-10H,1-7H2
|
|
InChIKey |
ORLQHILJRHBSAY-UHFFFAOYSA-N
|
|
Synonyms |
1,1-Cyclohexanedimethanol; 2658-60-8; [1-(hydroxymethyl)cyclohexyl]methanol; Cyclohexane-1,1-dimethanol; cyclohexane-1,1-diyldimethanol; NSC70173; 1,1-dimethylolcyclohexane; SCHEMBL15187; 1,1-di-hydroxymethylcyclohexane; DTXSID20949427; (Cyclohexane-1,1-diyl)dimethanol; (1-hydroxymethylcyclohexyl)methanol; ZINC1696148; Cyclohexane, 1,1-di-hydroxymethyl-; NSC-70173; AKOS017515623; AB89687; DS-020721; EN300-85223; A50718
|
|
CAS | 2658-60-8 | |
PubChem CID | 250594 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 144.21 | ALogp: | 1.1 |
HBD: | 2 | HBA: | 2 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 40.5 | Aromatic Rings: | 1 |
Heavy Atoms: | 10 | QED Weighted: | 0.614 |
Caco-2 Permeability: | -4.338 | MDCK Permeability: | 0.00002300 |
Pgp-inhibitor: | 0.002 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.005 | 20% Bioavailability (F20%): | 0.023 |
30% Bioavailability (F30%): | 0.505 |
Blood-Brain-Barrier Penetration (BBB): | 0.867 | Plasma Protein Binding (PPB): | 19.52% |
Volume Distribution (VD): | 0.86 | Fu: | 76.32% |
CYP1A2-inhibitor: | 0.406 | CYP1A2-substrate: | 0.341 |
CYP2C19-inhibitor: | 0.047 | CYP2C19-substrate: | 0.672 |
CYP2C9-inhibitor: | 0.032 | CYP2C9-substrate: | 0.081 |
CYP2D6-inhibitor: | 0.034 | CYP2D6-substrate: | 0.45 |
CYP3A4-inhibitor: | 0.058 | CYP3A4-substrate: | 0.203 |
Clearance (CL): | 6.556 | Half-life (T1/2): | 0.677 |
hERG Blockers: | 0.025 | Human Hepatotoxicity (H-HT): | 0.79 |
Drug-inuced Liver Injury (DILI): | 0.023 | AMES Toxicity: | 0.018 |
Rat Oral Acute Toxicity: | 0.006 | Maximum Recommended Daily Dose: | 0.073 |
Skin Sensitization: | 0.085 | Carcinogencity: | 0.981 |
Eye Corrosion: | 0.039 | Eye Irritation: | 0.977 |
Respiratory Toxicity: | 0.274 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001276 | 0.311 | D0J0ZS | 0.488 | ||||
ENC000592 | 0.280 | D0CK3G | 0.298 | ||||
ENC002918 | 0.267 | D0O3FG | 0.266 | ||||
ENC002922 | 0.246 | D0P1UX | 0.235 | ||||
ENC000251 | 0.243 | D0D0GV | 0.231 | ||||
ENC004216 | 0.233 | D03CEF | 0.214 | ||||
ENC000492 | 0.217 | D07XJM | 0.213 | ||||
ENC001222 | 0.216 | D03DVJ | 0.204 | ||||
ENC004836 | 0.213 | D00HWO | 0.200 | ||||
ENC005065 | 0.213 | D0X9RG | 0.198 |